トップ›研究者一覧›影本開三

研究者を探す

研究者にアプローチする
更新情報を通知する

影本開三

徳島大学

プロフィール
教育活動
研究活動
社会活動
リサーチマップ・
Jグローバル
KAKEN
注目研究

研究者総覧で最新データを確認する

2026年4月17日更新

職名: 特任准教授
電話: 研究者総覧に該当データはありませんでした。
電子メール: 研究者総覧に該当データはありませんでした。
学歴: 研究者総覧に該当データはありませんでした。
学位: 博士 / 博士(医学)
職歴・経歴: 2023/4: 徳島大学特任助教, 病院 (-2026.3.)
2026/4: 徳島大学特任准教授, 大学院医歯薬学研究部

専門分野・研究分野: 研究者総覧に該当データはありませんでした。

研究者総覧で最新データを確認する

2026年4月17日更新

専門分野・研究分野: 研究者総覧に該当データはありませんでした。
担当経験のある授業科目: 消化器・循環器 (学部)
指導経験: 研究者総覧に該当データはありませんでした。

研究者総覧で最新データを確認する

2026年4月17日更新

専門分野・研究分野: 研究者総覧に該当データはありませんでした。

研究テーマ: 研究者総覧に該当データはありませんでした。

著書

影本開三, 岡本耕一 :
Clostridioides difficile感染症(各論5 大腸60).,
日本医事新報社, 東京, 2025年12月. 影本開三, 岡本耕一 :
Column:Modified Underwater EMR.,
文光堂, 2025年10月. 影本開三, 岡本耕一, 高山哲治 :
1．消化管疾患大腸ポリープ, ポリポーシス, 大腸腺腫.,
総合医学社, 東京, 2025年3月. 影本開三, 岡本耕一, 高山哲治 :
大腸ポリープ・ポリポーシス・大腸腺腫(1. 消化管疾患).,
総合医学社, 東京, 2021年4月.

論文

Kaizo Kagemoto, Koichi Okamoto, Yoji Takeuchi, Yasuyuki Okada, Motoko Sei, shota Fujimoto, Ryo Shinomiya, Takeshi Mitsuhashi, Takanori Yoshimoto, Reiko Yokoyama, Tomoyuki Kawaguchi, Yoshifumi Kida, Yasuhiro Mitsui, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama :
Feasibility Study of Modified Underwater Endoscopic Mucosal Resection for Colorectal Polyps.,
DEN Open, 6, 1, e70294, 2026.

(要約): Underwater endoscopic mucosal resection (UEMR) is widely performed for colorectal tumors. However, in our experience, it is sometimes difficult to keep a clear endoscopic view underwater, due to dirty fluid inflow or insufficient water pooling after grasping the polyp, or bleeding just after endoscopic resection. To compensate for such challenges, we reported modified UEMR (M-UEMR) as a procedure for snaring underwater and undergas resection. Therefore, we conducted a prospective clinical trial to investigate the safety and efficacy of M-UEMR. This single-center prospective study was conducted at Tokushima University Hospital. Patients with 10-25 mm colorectal polyps were enrolled. The polyps were snared underwater, then infused water was removed, and the lumen was inflated with CO₂ for resection, as described in our previous report. Measured outcomes were R0 resection rate and adverse events such as bleeding, perforation, and post-polypectomy syndrome. In addition, we evaluated the en bloc resection rate and thickness of submucosal (SM) tissue of the resected specimens. Forty patients were enrolled, and the R0 resection rate was 80% (95% confidence interval [CI]: 64.4-90.9). No procedure-related adverse events were observed. En bloc resection was 92.5% (95% CI: 79.6-98.4). The median thickness of SM tissue (range) was 574 µm (241-2632) at the center of the specimen. M-UEMR demonstrated a high R0 resection rate with a safe profile. M-UEMR is expected to be utilized as an alternative technique to UEMR for colorectal polyps in patients with difficulty maintaining a clear visual field.
(出版サイトへのリンク): ● Publication site (DOI): 10.1002/deo2.70294
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 41693741; ● Search Scopus @ Elsevier (PMID): 41693741; ● Search Scopus @ Elsevier (DOI): 10.1002/deo2.70294

(DOI: 10.1002/deo2.70294, PubMed: 41693741) Koichi Okamoto, Ryo Shinomiya, Hiroyuki Ueda, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yasuyuki Okada, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto, Yasushi Sato and Tetsuji Takayama :
The Future Pioneered by Intestinal Organoid Culture Technology.,
The Journal of Medical Investigation : JMI, 72, 3-4, 235-240, 2025.

(要約): Intestinal organoids are three-dimensional cell culture models that replicate the structure and function of the intestine, and have drawn significant attention in recent years for their potential in research and medical applications. Organoid culture technology enables the reconstruction of miniature tissues with intestinal structures, often referred to as "mini-organs", from adult stem cells or induced pluripotent stem cells. This technology allows for the faithful replication of intestinal functions and pathologies that are challenging to reproduce using conventional two-dimensional culture systems. As a result, organoid culture has emerged as a vital platform that is widely utilized in developmental biology, disease modeling, drug screening, and personalized medicine. This article focuses on the clinical applications of organoid culture technology, particularly with respect to the gastrointestinal tract, and provides an overview of its advancements and clinical potential. J. Med. Invest. 72 : 235-240, August, 2025.
(キーワード): Organoids / Humans / Intestines / Cell Culture Techniques / Animals / Induced Pluripotent Stem Cells
(徳島大学機関リポジトリ): ● Metadata: 2013636
(出版サイトへのリンク): ● Publication site (DOI): 10.2152/jmi.72.235
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 41183920; ● Search Scopus @ Elsevier (PMID): 41183920; ● Search Scopus @ Elsevier (DOI): 10.2152/jmi.72.235

(徳島大学機関リポジトリ: 2013636, DOI: 10.2152/jmi.72.235, PubMed: 41183920) Yasuhiro Mitsui, Yasushi Sato, Ryo Shinomiya, Satoshi Sumida, Shota Fujimoto, Akiko Okada, Takeshi Mitsuhashi, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Koichi Okamoto, Hisanori Uehara and Tetsuji Takayama :
Case Report: Zolbetuximab-induced gastritis with protein-losing gastroenteropathy and hypogammaglobulinemia: a case implicating IgA vasculitis,
Frontiers in Oncology, 15, 1644263, 2025.

(キーワード): Claudin-18.2 / gastric cancer / gastritis / hypoalbuminemia / hypogammaglobulinemia / IgA vasculitis / protein-losing gastroenteropathy / zolbetuximab
(出版サイトへのリンク): ● Publication site (DOI): 10.3389/fonc.2025.1644263
(文献検索サイトへのリンク): ● Summary page in Scopus @ Elsevier: 2-s2.0-105012982726

(DOI: 10.3389/fonc.2025.1644263, Elsevier: Scopus) Koichi Okamoto, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Masahiro Sogabe, Yasushi Sato and Tetsuji Takayama :
Tip-fixing underwater endoscopic mucosal resection without submucosal injection for a laterally spreading colon polyp,
VideoGIE, 10, 8, 425-427, 2025.

(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.vgie.2025.03.034
(文献検索サイトへのリンク): ● Summary page in Scopus @ Elsevier: 2-s2.0-105004231786

(DOI: 10.1016/j.vgie.2025.03.034, Elsevier: Scopus) Kaizo Kagemoto, Koichi Okamoto, Yasuyuki Okada, Motoko Sei, Shota Fujimoto, Mai Yagi, Takeshi Mitsuhashi, Hiroyuki Ueda, Takanori Yoshimoto, Takanori Kashihara, Tomoyuki Kawaguchi, Yoshifumi Kida, Yasuhiro Mitsui, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto, Yasushi Sato, Naoki Muguruma and Tetsuji Takayama :
Clinicopathological evaluation of the efficacy of endoscopic treatment for sessile serrated lesions comparing endoscopic mucosal resection, cold snare polypectomy, and underwater endoscopic mucosal resection.,
DEN Open, 5, 1, e70051, 2025.

(要約): Recently, various endoscopic treatments for colorectal polyps have been reported, including cold snare polypectomy (CSP) and underwater endoscopic mucosal resection (UEMR), in addition to EMR. However, a precise treatment strategy for sessile serrated lesions (SSL) has not been established. In this study, we analyzed the clinicopathological features of SSL resected by EMR, CSP, and UEMR to determine the most suitable treatment for SSL. A total of 92 SSL resected via EMR ( = 11), CSP ( = 36), and UEMR ( = 45) were retrospectively enrolled between February 2021 and October 2022. To evaluate pathological findings, we examined SSL samples, which were stretched before formalin fixation and sectioned at 2-mm intervals. Primary outcomes were the R0 resection rate and thickness of submucosal (SM) tissue specimens for each treatment. In addition, we evaluated SSL with dysplasia (SSLD) and the inverted growth pattern which may affect the vertical margin. The R0 resection rate significantly differed among the three groups (EMR, 73%; CSP, 42%; UEMR, 87%, = 0.001). The median thickness of SM tissue resected by CSP (0 µm) was significantly less than that by EMR (362 µm) and UEMR (325 µm; < 0.001). All four SSLDs were diagnosed endoscopically. Five SSLs with inverted growth patterns were pathologically diagnosed. Of these, two SSLs with inverted growth patterns could not be diagnosed endoscopically. UEMR is considered to be a suitable treatment option for SSL. CSP results were pathologically insufficient. Therefore, surveillance to evaluate local recurrence is important, and the results of further multicenter prospective studies should be referred.
(出版サイトへのリンク): ● Publication site (DOI): 10.1002/deo2.70051
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39758158; ● Search Scopus @ Elsevier (PMID): 39758158; ● Search Scopus @ Elsevier (DOI): 10.1002/deo2.70051

(DOI: 10.1002/deo2.70051, PubMed: 39758158) Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Takanori Kashihara, Shota Fujimoto, Tomoyuki Kawaguchi, Reiko Yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
Metabolic dysfunction-associated steatotic liver disease and gallbladder polyp development: an observational study.,
Scientific Reports, 14, 1, 22446, 2024.

(要約): The influence of metabolic dysfunction-associated steatotic liver disease (MASLD) on gallbladder polyp development in both sexes remains elusive. Therefore, to clarify the role of MASLD in gallbladder polyp development, we investigated the longitudinal association between MASLD and gallbladder polyps. In this observational study, we included 5,527 gallbladder polyp-free patients who underwent > 2 health check-ups over > 2 years. Generalized estimation equations were used to analyze associations between MASLD and gallbladder polyp development according to repeated measures at baseline and the most recent stage. Gallbladder polyp development rates in men and women were 7.5% and 5.6% (p < 0.01), respectively. MASLD was not significantly correlated with gallbladder polyp development. Regarding the association between gallbladder polyp development (men: ≥6 mm and women: ≥5 mm) and the number of MASLD components following lifestyle habits, men and women with ≥ 4 MASLD components had odds ratios of 3.397 (95% confidence interval: 1.096-10.53) and 5.338 (1.054-27.04), respectively. Higher nonalcoholic fatty liver disease fibrosis scores were associated with significant risk of gallbladder polyp development in women (1.991, 1.047-3.785). Although MASLD influence on gallbladder polyp development differs by sex, close monitoring of patients with an increasing number of MASLD components is essential to prevent gallbladder polyp development. Specifically, men with ≥ 4 MASLD components should be monitored for gallbladder polyps measuring ≥ 6 mm.
(キーワード): Humans / Male / Female / Middle Aged / Polyps / Gallbladder Diseases / Adult / Risk Factors / Gallbladder / Non-alcoholic Fatty Liver Disease / Fatty Liver / Aged
(徳島大学機関リポジトリ): ● Metadata: 2012807
(出版サイトへのリンク): ● Publication site (DOI): 10.1038/s41598-024-73429-1
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39341964; ● Summary page in Scopus @ Elsevier: 2-s2.0-85205335685

(徳島大学機関リポジトリ: 2012807, DOI: 10.1038/s41598-024-73429-1, PubMed: 39341964, Elsevier: Scopus) Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Takanori Kashihara, Ryo Shinomiya, Takanori Miyake, Tomoyuki Kawaguchi, Reiko Yokoyama, Kaizo Kagemoto, Yoshifumi Kida, Yasuyuki Okada, Tetsu Tomonari, Yutaka Kawano, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
The association between alcohol consumption and cardiometabolic factors and liver fibrosis in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated liver disease.,
Alimentary Pharmacology & Therapeutics, 60, 11-12, 1587-1598, 2024.

(要約): The relationships between alcohol consumption, cardiometabolic factors, and liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease and those with metabolic dysfunction and alcohol-associated liver disease remain unclear. To investigate the longitudinal associations among alcohol consumption, cardiometabolic factors, and liver fibrosis in patients with these two liver diseases. This observational cohort study included 1866 patients with metabolic dysfunction-associated steatotic liver disease and 521 patients with metabolic dysfunction and alcohol-associated liver disease who underwent > two health checkups over >2 years. The associations of both liver diseases with worsening non-invasive liver fibrosis scores were assessed using the Cox regression analysis. Both liver diseases independently worsened liver fibrosis in both sexes. However, the hazard ratio for worsening liver fibrosis in females was significantly higher with metabolic dysfunction and alcohol-associated liver disease than with metabolic dysfunction-associated steatotic liver disease. Worsening liver fibrosis was not associated with alcohol consumption. Among males with metabolic dysfunction-associated steatotic liver disease, the hazard ratio for worsening liver fibrosis was significantly higher in those with multiple cardiometabolic factors compared to those with a single cardiometabolic factor. Although both metabolic steatotic liver disease and metabolic alcohol-associated liver disease were correlated with liver fibrosis progression in both sexes, the impact of alcohol consumption and cardiometabolic factors on fibrosis progression differed by sex. Cardiometabolic factors may have a stronger impact on liver fibrosis than alcohol consumption in males with metabolic dysfunction-associated steatotic liver disease.
(キーワード): Humans / Male / Female / Middle Aged / Alcohol Drinking / Liver Cirrhosis / Adult / Cohort Studies / Aged / Liver Diseases, Alcoholic / Fatty Liver / Risk Factors / Sex Factors
(徳島大学機関リポジトリ): ● Metadata: 2013146
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/apt.18280
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 39310953; ● Search Scopus @ Elsevier (PMID): 39310953; ● Search Scopus @ Elsevier (DOI): 10.1111/apt.18280

(徳島大学機関リポジトリ: 2013146, DOI: 10.1111/apt.18280, PubMed: 39310953) Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Hiroyuki Ueda, reiko yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Yutaka Kawano, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
Association of metabolic dysfunction-associated steatotic liver disease with erosive esophagitis development: a longitudinal observational study.,
Journal of Gastroenterology and Hepatology, 39, 6, 1107-1114, 2024.

(要約): Although erosive esophagitis (EE) is associated with fatty liver and metabolic dysregulation, the association between EE and metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear. Thus, this study aimed to investigate the longitudinal association between MASLD and EE. We included 1578 patients without EE at baseline who underwent more than two health checkups over 2 years. Generalized estimation equations were used to analyze associations between MASLD and EE according to repeated measures at baseline and most recent stages. EE development rates in men and women were 14.5% and 7.2%, respectively. After adjusting for lifestyle habits, the odds ratios of MASLD for EE development in men and women were 1.907 (95% confidence interval [CI]: 1.289-2.832, P < 0.005) and 1.483 (95% CI: 0.783-2.811, P = 0.227), respectively. In the subgroup analysis, after adjusting for lifestyle habits, among men and women aged 50 years with more than three MASLD components, the odds ratios for EE development were 2.408 (95% CI: 1.505-3.855, P < 0.001) and 2.148 (95% CI: 1.093-4.221, P < 0.05), respectively. After adjusting for various factors, the significant risk factors for EE development were different between men and women. The influence of MASLD and other factors on EE development differed by sex and age. Particularly, patients aged 50 years with MASLD and with an increased number of MASLD components should be considered at increased risk for EE.
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/jgh.16530
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38419514; ● Search Scopus @ Elsevier (PMID): 38419514; ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.16530

(DOI: 10.1111/jgh.16530, PubMed: 38419514) Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Hiroyuki Ueda, reiko yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
Association of variabilities in body mass index and waist circumference with newly achieved remission of metabolic dysfunction-associated fatty liver disease.,
Diabetes & Metabolic Syndrome, 18, 5, 103036, 2024.

(要約): Although body weight reduction is recommended to ameliorate nonalcoholic fatty liver disease, the effects of body mass index (BMI) and waist circumference (WC) variability on newly achieved remission of metabolic dysfunction-associated fatty liver disease (MAFLD) remain unclear. We aimed to investigate the longitudinal association between BMI and WC variabilities and newly achieved MAFLD remission in both sexes. Among 26,952 patients, 1823 with MAFLD diagnosed by ultrasonography and with >2 health checkups over >2 years from April 2014 to March 2021 were included in this observational cohort study. A generalized estimation equation model analyzed the association between BMI and WC and newly achieved MAFLD remission according to repeated measures at baseline and the most recent stage. Rates of MAFLD remission in male and female patients were 7.4 % and 6.0 %, respectively. Regarding decreased BMI variability, newly achieved MAFLD remission prevalence among the subgroups differed significantly between sexes (p < 0.001). In male patients, a decrease in BMI variability of ≥1.5 kg/m and WC variability of ≥4.2 cm had adjusted odds ratios (ORs) of 5.215 and 2.820, respectively, for newly achieved MAFLD remission. Among female patients, regular exercise and breakfast consumption were accelerating factors for newly achieved MAFLD remission. Non-invasive liver fibrosis scores significantly differed between MAFLD and newly achieved MAFLD remission, including in the subgroups (p < 0.01 and p < 0.001, respectively). Reducing BMI and WC variabilities in male patients and improving lifestyle habits in female patients may accelerate MAFLD remission.
(キーワード): Humans / Male / Female / Body Mass Index / Middle Aged / Non-alcoholic Fatty Liver Disease / Waist Circumference / Adult / Remission Induction / Follow-Up Studies / Prognosis / Metabolic Diseases
(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.dsx.2024.103036
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38754333; ● Search Scopus @ Elsevier (PMID): 38754333; ● Search Scopus @ Elsevier (DOI): 10.1016/j.dsx.2024.103036

(DOI: 10.1016/j.dsx.2024.103036, PubMed: 38754333) Koichi Okamoto, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Fumika Nakamura, Kouzou Yoshikawa, Masahiro Sogabe, Yasushi Sato, Joji Shunto, Yoshimi Bando, Mitsuo Shimada and Tetsuji Takayama :
Gastric fundic gland polyposis and cancer development after eradication of Helicobacter pylori in patient with gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS).,
Gastric Cancer, 27, 3, 635-640, 2024.

(要約): A 44-year-old woman with gastric cancer (GC) and fundic gland polyposis (FGPs) was referred to our hospital for further diagnosis and treatment. She successfully underwent eradication therapy for Helicobacter pylori (HP) 6 years ago, but did not exhibit FGPs at that time. When she underwent an esophagogastroduodenoscopy 2, 4, and 5 years after the eradication of HP, her imaging results revealed the existence of FGPs which gradually increased in her gastric fundus and body. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS) was suspected and a mutational analysis was performed, revealing an APC promoter 1B variant c.-191T > C. A robotic total gastrectomy with lymphadenectomy was performed. Histopathological analysis of the surgical specimens revealed GC with no lymph node metastasis. GAPPS is characterized by GC and FGPs. However, our case shows different gastric phenotypes that are dependent on the status of HP infection.
(キーワード): Female / Humans / Adult / Stomach Neoplasms / Helicobacter pylori / Adenocarcinoma / Helicobacter Infections / Polyps / Adenomatous Polyps
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s10120-024-01473-x
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38407681; ● Search Scopus @ Elsevier (PMID): 38407681; ● Search Scopus @ Elsevier (DOI): 10.1007/s10120-024-01473-x

(DOI: 10.1007/s10120-024-01473-x, PubMed: 38407681) Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Takanori Kashihara, shota Fujimoto, Tomoyuki Kawaguchi, Reiko Yokoyama, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Yutaka Kawano, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
Impact of alcohol consumption on metabolic dysfunction-associated fatty liver disease development and remission: A longitudinal cohort study.,
European Journal of Clinical Investigation, 54, 9, e14221, 2024.

(要約): The influence of alcohol intake on metabolic dysfunction-associated fatty liver disease (MAFLD) development and remission remains unclear; thus, we aimed to investigate their longitudinal associations. This observational cohort study included 6349 patients who underwent more than two health check-ups over >2 years between April 2013 and March 2021. Generalized estimation equations were used to analyse the longitudinal associations between changes in alcohol intake and MAFLD according to repeated measures at baseline and the most recent stage. The MAFLD development and remission rates were 20.4 and 5.1 and 9.1 and 4.7% in men and women, respectively. Although alcohol consumption was not a significant factor for MAFLD development, consuming 0.1-69.9 g/week (odds ratio [OR]: 0.672, 95% confidence interval [CI]: 0.469-0.964, p < .05) and 280 g/week were significant factors for MAFLD development in males (OR: 1.796, 95% CI: 1.009-3.196, p < .05) and females (OR: 16.74, 95% CI: 3.877-72.24, p < .001). Regardless of quantity and frequency, alcohol consumption was not a significant factor for MAFLD remission. Several noninvasive liver fibrosis scores were significantly associated with alcohol intake quantity and frequency in males with MAFLD development and remission (p < .05). The nonalcoholic fatty liver disease fibrosis score differed significantly between males with and without reduced alcohol intake (p < .05) who showed MAFLD remission. Although the influence of alcohol intake on MAFLD development and remission differed, alcohol consumption was not beneficial for MAFLD remission in either sex. Alcohol intake reduction or cessation is recommended to prevent liver fibrosis, even in those who achieve MAFLD remission.
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/eci.14221
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38634705; ● Search Scopus @ Elsevier (PMID): 38634705; ● Search Scopus @ Elsevier (DOI): 10.1111/eci.14221

(DOI: 10.1111/eci.14221, PubMed: 38634705) Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Motoko Sei, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Fumika Nakamura, Tetsu Tomonari, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
Association of metabolic dysfunction-associated fatty liver disease with gallstone development: A longitudinal study.,
Journal of Gastroenterology and Hepatology, 39, 4, 754-761, 2024.

(要約): The influence of metabolic dysfunction-associated fatty liver disease on gallstone development remains unclear. We aimed to investigate the longitudinal association between metabolic dysfunction-associated fatty liver disease and gallstone development in both men and women. This observational cohort study included 5398 patients without gallstones who underwent > 2 health check-ups between April 1, 2014, and March 31, 2020. A generalized estimation equation model was used to analyze the association between metabolic dysfunction-associated fatty liver disease and gallstone development according to repeated measures at baseline and most recent stage. After adjustment, the odds ratios of metabolic dysfunction-associated fatty liver disease for gallstone development in men and women were 3.019 (95% confidence interval [CI]: 1.901-4.794) and 2.201 (95% CI: 1.321-3.667), respectively. Among patients aged 50 years, the odds ratio for gallstone development was significantly enhanced with increasing metabolic dysfunction-associated fatty liver disease component numbers in both sexes; however, no significance was observed in those aged < 50 years. Other significant risk factors for gallstone development were age (odds ratio: 1.093, 95% CI: 1.060-1.126) and waist circumference (odds ratio: 1.048, 95% CI: 1.018-1.079) in men and age (odds ratio: 1.035, 95% CI: 1.003-1.067) and current smoking (odd ratio: 5.465, 95% CI: 1.881-15.88) in women. Although the risk factors for gallstone development differed between sexes, metabolic dysfunction-associated fatty liver disease was common. Paying attention to an increase in the number of metabolic dysfunction-associated fatty liver disease components in patients aged 50 years is important for gallstone prevention.
(出版サイトへのリンク): ● Publication site (DOI): 10.1111/jgh.16483
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 38212880; ● Search Scopus @ Elsevier (PMID): 38212880; ● Search Scopus @ Elsevier (DOI): 10.1111/jgh.16483

(DOI: 10.1111/jgh.16483, PubMed: 38212880) Reiko Yokoyama, Yasushi Sato, Fumika Nakamura, Kaizo Kagemoto, Yasuhiro Mitsui, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto and Tetsuji Takayama :
Efficacy of immune checkpoint inhibitors in patients with anorectal melanoma in association with immune-related adverse events: a case series.,
Clinical Journal of Gastroenterology, Online ahead of print., 2023.

(要約): Anorectal melanoma (AM) is a rare subtype of mucosal melanoma with a poor prognosis. Given its rarity compared to its cutaneous counterpart, the benefits and side effects of immune checkpoint inhibitor (ICI) therapy and the relationship between side effects and prognosis remain unclear. Herein, we describe the clinical presentation of five patients with AM treated with ICI as well as their relationship to the treatment course and the development of immune-related adverse events (irAEs). Three patients received sequential or concurrent administrations of nivolumab and ipilimumab, one received nivolumab alone, and one received ipilimumab alone. The response rate (RR) and disease control rate (DCR) were 40% and 80%, respectively. Pituitary and hepatic dysfunctions were the most common irAEs observed (40% each), followed by thyroid, diarrhea, and renal dysfunctions (20% each). The RR was 67% in patients with irAEs while no response was observed in patients without irAEs. DCR was 100% and 50% in patients with and without irAEs, respectively. Overall survival was 34 months in irAE and 8.75 months in non-irAE cases, with a longer survival trend in irAE cases. ICI therapy was effective and well-tolerated by AM patients, with potentially better outcomes for those who experienced irAEs compared to those who did not.
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-023-01849-z
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37632658; ● Summary page in Scopus @ Elsevier: 2-s2.0-85169147432

(DOI: 10.1007/s12328-023-01849-z, PubMed: 37632658, Elsevier: Scopus) Koichi Okamoto, Tomoyuki Kawaguchi, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Yasushi Sato and Tetsuji Takayama :
Tip-in underwater endoscopic mucosal resection without submucosal injection for superficial nonampullary duodenal adenomas,
Endoscopy, 55, S 01, E965-E966, 2023.

(キーワード): Humans / Endoscopic Mucosal Resection / Duodenal Neoplasms / Duodenum / Injections
(出版サイトへのリンク): ● Publication site (DOI): 10.1055/a-2134-9080
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37604451; ● Summary page in Scopus @ Elsevier: 2-s2.0-85168452995

(DOI: 10.1055/a-2134-9080, PubMed: 37604451, Elsevier: Scopus) Masahiro Sogabe, Toshiya Okahisa, Miwako Kagawa, Hiroyuki Ueda, Kaizo Kagemoto, Hironori Tanaka, Yoshifumi Kida, Tetsu Tomonari, Tatsuya Taniguchi, Koichi Okamoto, Hiroshi Miyamoto, Yasushi Sato, Masahiko Nakasono and Tetsuji Takayama :
Influence of alcohol on newly developed metabolic dysfunction-associated fatty liver disease in both sexes: A longitudinal study.,
Clinical Nutrition, 42, 5, 810-816, 2023.

(要約): The influence of changes in alcohol consumption on newly developed metabolic dysfunction-associated fatty liver disease (MAFLD) is unclear. We investigated the influence of alcohol consumption on newly developed MAFLD in both sexes. This observational cohort study included 4071 patients who underwent more than two health check-ups between 2015 and 2020 over an interval of more than a year. Generalised estimating equations were used for analyses. At baseline, the rates of drinking and MAFLD between men and women were 72.5% versus 41.7% and 42.2% versus 22.1%, respectively. At the most recent stage, the rates of an increase in alcohol consumption for men and women were 13.3% and 8.7%, respectively, and 311/1192 (26.1%) men and 155/1566 (9.9%) women had newly developed MAFLD. The odds ratio (OR) for drinking in patients with newly developed MAFLD was 0.863 (men) (95% confidence interval [CI], 0.676-1.102, p = 0.237) and 1.041 (women) (95% CI, 0.753-1.439, p = 0.808); the OR for women who drank 140-279.9 g/week was 2.135 (95% CI, 1.158-3.939, p < 0.05) and that for all drinking categories among women was >1. Several non-invasive fibrosis scores were significantly associated with the quantity of alcohol consumption in patients with newly developed MAFLD (p < 0.005). Alcohol consumption had no significant protective effect against newly developed MAFLD in both sexes, regardless of quantity. Conversely, alcohol consumption ≥140 g/week was a risk factor for newly developed MAFLD in women. The development of liver fibrosis with increased alcohol intake should be considered in patients with MAFLD.
(徳島大学機関リポジトリ): ● Metadata: 2011328
(出版サイトへのリンク): ● Publication site (DOI): 10.1016/j.clnu.2023.03.020
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 37043935; ● Search Scopus @ Elsevier (PMID): 37043935; ● Search Scopus @ Elsevier (DOI): 10.1016/j.clnu.2023.03.020

(徳島大学機関リポジトリ: 2011328, DOI: 10.1016/j.clnu.2023.03.020, PubMed: 37043935) Megumi Yamasaki, Yasushi Sato, Koichi Okamoto, Akira Fukuya, Tomoyuki Kawaguchi, Kazuyoshi Noda, Kaizo Kagemoto, Yasuhiro Mitsui, Hiroshi Miyamoto and Tetsuji Takayama :
Two cases of anal squamous cell carcinoma achieving complete response after docetaxel + cisplatin + S1 (DCS) induction chemotherapy followed by chemoradiation.,
Clinical Journal of Gastroenterology, 16, 2, 180-186, 2022.

(要約): Anal squamous cell carcinoma (ASCC) is an uncommon tumor. However, its incidence is increasing worldwide. Surgical resection of locally advanced cases requires permanent anal prosthesis. Thus, chemoradiotherapy (CRT) is preferred as the first-line treatment; however, high local recurrence rate remains an issue. Here, we describe two cases of locally advanced ASCC treated with docetaxel + cisplatin + S-1 (DCS) followed by CRT with S-1 that showed complete response. The two patients, aged 69 and 65 years, were diagnosed with ASCC (cStage IIIB) at our hospital. Due to extensive lymph node metastases, the patients were treated with triple induction chemotherapy (DCS) followed by CRT with S-1. Positron emission tomography/computed tomography performed six months after starting the treatment showed disappearance of tumors, indicating a complete response. The patients continued to receive S-1 for one year and achieved relapse-free long-term survival since the completion of treatment. Therefore, induction chemotherapy with DCS, prior to CRT with S-1 may benefit patients with locally advanced ASCC.
(出版サイトへのリンク): ● Publication site (DOI): 10.1007/s12328-022-01736-z
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36409453; ● Search Scopus @ Elsevier (PMID): 36409453; ● Search Scopus @ Elsevier (DOI): 10.1007/s12328-022-01736-z

(DOI: 10.1007/s12328-022-01736-z, PubMed: 36409453) 和田浩典, 藤野泰輝, 影本開三, 喜田慶史, 岡田泰行, 三井康裕, 岡本耕一, 佐藤康史, 坂東良美, 宮本弘志, 高山哲治 :
がん遺伝子パネル検査を契機にHER2陽性が判明しTrastuzumab投与により長期生存が得られた進行胃癌の1例.,
日本消化器病学会雑誌, 119, 10, 937-945, 2022年.

(要約): Intratumoral HER2 heterogeneity is a well-described gastric cancer feature and may explain many false-negative results related to this oncogene. An 81-year-old man was diagnosed at our hospital with stage IV gastric cancer with multiple lymph node metastases. Immunohistochemistry (IHC) analysis indicated that the primary tumor was HER2-negative. After a chemotherapy course, we submitted a pretreatment biopsy specimen for comprehensive cancer genome profiling (CGP) to determine the last-line therapy. This revealed HER2 amplification. The specimen was reevaluated using fluorescence in situ hybridization and IHC with deeper-cut specimens, which confirmed that the tumor was indeed HER2-positive. Therefore, the patient was treated with chemotherapy plus trastuzumab, which elicited tumor shrinkage and conferred long-term survival. Our current data underscore the CGP importance, which can provide more accurate tumor profilings and inform subsequent treatment decisions.
(キーワード): がん遺伝子パネル検査 / Trastuzumab / HER2陽性胃癌
(出版サイトへのリンク): ● Publication site (DOI): 10.11405/nisshoshi.119.937
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 36216544; ● CiNii @ 国立情報学研究所 (CRID): 1390293710918867840; ● Search Scopus @ Elsevier (PMID): 36216544; ● Search Scopus @ Elsevier (DOI): 10.11405/nisshoshi.119.937

(DOI: 10.11405/nisshoshi.119.937, PubMed: 36216544, CiNii: 1390293710918867840) Kaizo Kagemoto, Yoji Takeuchi and Koichi Okamoto :
Modified underwater endoscopic mucosal resection for a laterally spreading tumor: Underwater snaring and undergas resection.,
Digestive Endoscopy, 34, 3, e32-e33, 2021.

(出版サイトへのリンク): ● Publication site (DOI): 10.1111/den.14203
(文献検索サイトへのリンク): ● PubMed @ National Institutes of Health, US National Library of Medicine (PMID): 34888959; ● Search Scopus @ Elsevier (PMID): 34888959; ● Search Scopus @ Elsevier (DOI): 10.1111/den.14203

(DOI: 10.1111/den.14203, PubMed: 34888959)

MISC

研究者総覧に該当データはありませんでした。

総説・解説: 岡本耕一, 三井康裕, 吉本貴則, 藤本将太, 三橋威志, 上田浩之, 横山怜子, 川口智之, 影本開三, 喜田慶史, 中村文香, 佐藤康史, 春藤譲治, 坂東良美, 九嶋亮治, 高山哲治 :
遺伝性胃癌:病態解析と診断の進歩胃腺癌および近位胃ポリポーシス(GAPPS)を中心に.,
胃と腸, 58, 12, 1589-1601, 2023年12月.
講演・発表: Takeshi Mitsuhashi, Yutaka Kawano, Masahiro Bando, Tetsu Tomonari, Hironori Tanaka, Mai Yonezawa, Kohei Hanada, Masahiro Sogabe, Kaizo Kagemoto, Yasuyuki Okada, Yasushi Sato and Tetsuji Takayama :
Genome-wide CRISPR SCREEN identifies ALDOA as a modifier of PARP inhibitor sensitivity in Hepatocellular Carcinoma.,
UEG Week 2025, Berlin, Oct. 2025. 三井康裕, 藤本将太, 西正暁, 住田智志, 三橋威志, 川口智之, 影本開三, 喜田慶史, 岡本耕一, 高山哲治 :
<パネルディスカッション>Zolbetuximab関連胃炎の臨床病理学的特徴および発生機序の解析.,
第112回日本消化器病学会総会, 2026年4月. 曽我部正弘, 香川美和子, 米田健一, 末内辰尚, 柴昌子, 四宮遼, 川口智之, 影本開三, 喜田慶史, 岡田泰行, 岡本耕一, 佐藤康史, 岡久稔也, 高山哲治 :
びらん性食道炎とoral microbiotaの関連性.,
第135回日本消化器内視鏡学会四国支部例会,徳島, 2025年11月. 四宮遼, 岡久稔也, 米田健一, 末内辰尚, 大木元彩夏, 横山怜子, 川口智之, 影本開三, 喜田慶史, 岡本耕一, 曽我部正弘, 大野将樹, 高山哲治 :
多数部位同時腸音解析システムを用いた腸音測定部位の最適化．,
第123回日本消化器病学会四国支部例会, 高知., 2025年6月. 岡田泰行, 佐藤康史, 影本開三, 喜田慶史, 田中宏典, 三井康裕, 岡本耕一, 河野豊, 宮本弘志, 高山哲治 :
切除不能膵癌におけるFOLFIRINOX 療法後のリポソーマルイリノテカンの治療効果の検討.,
第22回日本臨床腫瘍学会学術集会(JSMO2025), 2025年3月. 影本開三, 岡本耕一, 高山哲治 :
<ビデオワークショップ>大腸腫瘍に対するmodified underwater endoscopic mucosal resectionの有効性と安全性に関する前向き観察研究.,
第107回日本消化器内視鏡学会総会, 2024年5月. 川口智之, 岡本耕一, 三橋威志, 吉本貴則, 影本開三, 喜田慶史, 三井康裕, 中村文香, 佐藤康史, 高山哲治 :
<ワークショップ>Serrated polyposis syndromeの右側及び左側大腸病変の臨床病理学的差異の解析.,
第110回日本消化器病学会総会, 2024年5月. 吉本貴則, 岡本耕一, 上田浩之, 川口智之, 影本開三, 喜田慶史, 三井康裕, 中村文香, 佐藤康史, 高山哲治 :
<ワークショップ>Gastric adenocarcinoma and proximal polyposis of the stomach(GAPPS)の表現型とHelicobacter pylori(HP)感染症の関連についての検討.,
第110回日本消化器病学会総会, 2024年5月. 上田浩之, 藤本将太, 吉本貴則, 川口智之, 影本開三, 喜田慶史, 三井康裕, 岡本耕一, 佐藤康史, 高山哲治 :
<ワークショップ>ヒト由来大腸癌オルガノイドを用いたTIMP1の右側大腸癌の予後不良因子としての検討.,
第110回日本消化器病学会総会, 2024年5月. 福家慧, 佐藤康史, 岡田泰行, 岡本耕一, 河野豊, 宮本弘志, 高山哲治, 影本開三, 喜田慶史 :
UBR4 は EGFR の内在化を制御することで，大腸癌患者における抗 EGFR 抗体の新規バイオマーカーとなる.,
第21回日本臨床腫瘍学会学術集会, 2024年2月. 岡本耕一, 勢井萌都子, 藤本将太, 三橋威志, 吉本貴則, 川口智之, 影本開三, 喜田慶史, 三井康裕, 中村文香, 佐藤康史, 高山哲治 :
Serrated polyposis syndromeの右側及び左側大腸病変の臨床病理学的および分子生物学的解析,
第10回消化管ポリポーシス研究会, 2024年1月. 横山怜子, 佐藤康史, 中村文香, 川口智之, 影本開三, 喜田慶史, 三井康裕, 藤野泰輝, 岡本耕一, 河野豊, 宮本弘志, 高山哲治 :
直腸悪性黒色腫に対する免疫チェックポイント阻害剤の効果予測因子としての irAE の意義.,
第 61 回日本癌治療学会学術集会, 2023年10月. 大木元彩夏, 岡本耕一, 高橋叡, 藤本将太, 吉本貴則, 三橋威志, 川口智之, 影本開三, 喜田慶史, 三井康裕, 中村文香, 佐藤康史, 高山哲治 :
内視鏡による積極的大腸ポリープ摘除術を施行しているリンチ症候群の一例.,
第5回がんゲノム医療時代におけるLynch症候群研究会学術集会, 2023年8月. 影本開三, 岡本耕一, 高山哲治 :
Sessile serrated lesion(SSL)に対する内視鏡的切除法の検討,
第105回日本消化器内視鏡学会総会, 2023年5月. 川口智之, 岡久稔也, 曽我部正弘, 吉本貴則, 上田浩之, 影本開三, 喜田慶史, 三井康裕, 中村文香, 北村晋志, 岡本耕一, 宮本弘志, 佐藤康史, 高山哲治 :
特徴的な内視鏡像を呈しAzithromiycinによる治療が奏功したクラミジア直腸炎の一例.,
第117回日本消化器病学会四国支部例会, 松山., 2022年6月. 曽我部正弘, 岡久稔也, 栗原健士, 香川美和子, 柴昌子, 阿達由佳, 福家慧, 武原正典, 影本開三, 田中宏典, 平尾章博, 喜田慶史, 藤野泰輝, 友成哲, 谷口達哉, 北村晋志, 岡本耕一, 宮本弘志, 六車直樹, 高山哲治 :
映像・照明を用いた視覚刺激による上部消化管内視鏡検査受診者への循環動態・自律神経機能・心理状態の影響.,
第124回日本消化器内視鏡学会四国支部例会, 徳島., 2020年6月. 曽我部正弘, 岡久稔也, 藤野泰輝, 阿達由佳, 福家慧, 武原正典, 松本友里, 村山典聡, 影本開三, 岡崎潤, 岡田泰行, 田中宏典, 平尾章博, 高岡慶史, 友成哲, 郷司敬洋, 谷口達哉, 北村晋志, 木村哲夫, 岡本耕一, 木村雅子, 宮本弘志, 六車直樹, 高山哲治 :
<合同シンポジウム>上部消化管内視鏡検査前における映像・音・照明による循環動態・自律神経機能・心理状態への影響.,
第116回日本消化器内視鏡学会四国支部例会. 合同シンポジウム, 徳島, 2016年. 木村哲夫, 新居徹, 津保友香, 武原正典, 影本開三, 岡崎潤, 岡田泰行, 松本早代, 藤野泰輝, 田中久美子, 香川美和子, 北村晋志, 岡本耕一, 木村雅子, 曽我部正弘, 宮本弘志, 六車直樹, 岡久稔也, 高山哲治 :
<合同シンポジウム>切除不能進行膵癌に対する化学療法の進歩―GEM+nab-PTX併用療法の治療成績.,
第103回日本消化器病学会四国支部例会. 合同シンポジウム, 高松, 2015年6月.

研究会・報告書: 研究者総覧に該当データはありませんでした。

特許: 研究者総覧に該当データはありませんでした。
作品: 研究者総覧に該当データはありませんでした。
補助金・競争的資金: オルガノイドを用いた左右大腸癌の分子異常解析に基づく新規治療薬の開発 (研究課題/領域番号: 24K18976 )
口腔内細菌叢・内臓脂肪解析による新しい観点からのバレット食道進展メカニズムの解明 (研究課題/領域番号: 23K10961 )
左側及び右側大腸癌の分子生物学的差異の解析ー個別化及び層別化治療に向けてー (研究課題/領域番号: 22K15997 )
研究者番号（60933356）による検索

その他: 研究者総覧に該当データはありませんでした。

研究者総覧で最新データを確認する

2026年4月17日更新

専門分野・研究分野: 研究者総覧に該当データはありませんでした。
所属学会・所属協会: 研究者総覧に該当データはありませんでした。
委員歴・役員歴: 研究者総覧に該当データはありませんでした。
受賞: 研究者総覧に該当データはありませんでした。
活動: 研究者総覧に該当データはありませんでした。

更新

Ｊグローバル

Jグローバル最終確認日: JグローバルAPIで取得できませんでした。
氏名（漢字）: JグローバルAPIで取得できませんでした。
氏名（フリガナ）: JグローバルAPIで取得できませんでした。
氏名（英字）: JグローバルAPIで取得できませんでした。
所属機関: JグローバルAPIで取得できませんでした。

リサーチマップ

researchmap最終確認日: リサーチマップAPIで取得できませんでした。
氏名（漢字）: リサーチマップAPIで取得できませんでした。
氏名（フリガナ）: リサーチマップAPIで取得できませんでした。
氏名（英字）: リサーチマップAPIで取得できませんでした。
プロフィール: リサーチマップAPIで取得できませんでした。
登録日時: リサーチマップAPIで取得できませんでした。
更新日時: リサーチマップAPIで取得できませんでした。
アバター画像URI: リサーチマップAPIで取得できませんでした。
ハンドル: リサーチマップAPIで取得できませんでした。
eメール: リサーチマップAPIで取得できませんでした。
eメール（その他）: リサーチマップAPIで取得できませんでした。
携帯メール: リサーチマップAPIで取得できませんでした。
性別: リサーチマップAPIで取得できませんでした。
没年月日: リサーチマップAPIで取得できませんでした。
所属ID: リサーチマップAPIで取得できませんでした。
所属: リサーチマップAPIで取得できませんでした。
部署: リサーチマップAPIで取得できませんでした。
職名: リサーチマップAPIで取得できませんでした。
学位: リサーチマップAPIで取得できませんでした。
学位授与機関: リサーチマップAPIで取得できませんでした。
URL: リサーチマップAPIで取得できませんでした。
科研費研究者番号: リサーチマップAPIで取得できませんでした。
Google Analytics ID: リサーチマップAPIで取得できませんでした。
ORCID ID: リサーチマップAPIで取得できませんでした。
その他の所属ID: リサーチマップAPIで取得できませんでした。
その他の所属名: リサーチマップAPIで取得できませんでした。
その他の所属部署: リサーチマップAPIで取得できませんでした。
その他の所属職名: リサーチマップAPIで取得できませんでした。
最近のエントリー: リサーチマップAPIで取得できませんでした。
Read会員ID: リサーチマップAPIで取得できませんでした。
経歴: リサーチマップAPIで取得できませんでした。
受賞: リサーチマップAPIで取得できませんでした。
Misc: リサーチマップAPIで取得できませんでした。
論文: リサーチマップAPIで取得できませんでした。
講演・口頭発表等: リサーチマップAPIで取得できませんでした。
書籍等出版物: リサーチマップAPIで取得できませんでした。
研究キーワード: リサーチマップAPIで取得できませんでした。
研究分野: リサーチマップAPIで取得できませんでした。
所属学協会: リサーチマップAPIで取得できませんでした。
担当経験のある科目: リサーチマップAPIで取得できませんでした。
その他: リサーチマップAPIで取得できませんでした。
Works: リサーチマップAPIで取得できませんでした。
特許: リサーチマップAPIで取得できませんでした。
学歴: リサーチマップAPIで取得できませんでした。
委員歴: リサーチマップAPIで取得できませんでした。
社会貢献活動: リサーチマップAPIで取得できませんでした。

ＫＡＫＥＮで最新データを確認する

2026年4月18日更新

研究者番号: 60933356

所属（現在）: 2026/4/1 : 徳島大学, 大学院医歯薬学研究部(医学域), 特任准教授

所属（過去の研究課題 情報に基づく）*注記: 2023/4/1 – 2024/4/1 : 徳島大学, 病院, 特任助教
2022/4/1 : 徳島大学, 病院, 医員

審査区分/研究分野

研究代表者

小区分53010:消化器内科学関連

研究代表者以外

小区分59040:栄養学および健康科学関連

キーワード

研究代表者

大腸癌 / オルガノイド / メチレーションアレイ

研究代表者以外

逆流性食道炎 / バレット食道

研究課題研究成果共同研究者

「研究課題をさがす」で表示
テキスト（CSV）で出力

テキスト（CSV）で出力

注目研究はありません。

研究者を探す

影本 開三

Ｊグローバル

リサーチマップ

研究代表者

研究代表者以外

研究代表者

研究代表者以外

影本開三